KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Receivables (2016 - 2025)

Historic Receivables for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $978590.0.

  • Inovio Pharmaceuticals' Receivables fell 4746.5% to $978590.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $978590.0, marking a year-over-year decrease of 4746.5%. This contributed to the annual value of $1.2 million for FY2024, which is 5014.79% down from last year.
  • According to the latest figures from Q3 2025, Inovio Pharmaceuticals' Receivables is $978590.0, which was down 4746.5% from $840312.0 recorded in Q2 2025.
  • Inovio Pharmaceuticals' Receivables' 5-year high stood at $20.1 million during Q4 2022, with a 5-year trough of $840312.0 in Q2 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' median Receivables value was $5.0 million (recorded in 2023), while the average stood at $6.0 million.
  • In the last 5 years, Inovio Pharmaceuticals' Receivables surged by 70408.89% in 2021 and then crashed by 8801.76% in 2023.
  • Over the past 5 years, Inovio Pharmaceuticals' Receivables (Quarter) stood at $8.0 million in 2021, then skyrocketed by 149.91% to $20.1 million in 2022, then tumbled by 88.02% to $2.4 million in 2023, then tumbled by 50.15% to $1.2 million in 2024, then fell by 18.39% to $978590.0 in 2025.
  • Its Receivables stands at $978590.0 for Q3 2025, versus $840312.0 for Q2 2025 and $1.3 million for Q1 2025.